OSIMERITINIB 80MG |TAGRISSO 80MG | MILLIONHEALTHPHARMA

OSIMERITINIB 80MG

DESCRIPTION

Tagrisso,Tagrisso 80mg,Tagrisso 80mg tablet

A Tagrisso 80mg tablet is containing an active substance known as Osimeritinib, which is formerly known as Mereletinib.

Tagrisso 80mg is considered as third generation medicine, which is available in tablet form.

Tagrisso 80mg is an inevitable, selectively deviated epidermal growth factor receptor prohibitor, containing anti-cancer activity.

The pharmacological category of Tagrisso 80mg tablet is tyrosine kinase prohibitor.

INDICATION

Tagrisso 80mg

A Tagrisso 80mg tablet is widely indicated as first line therapy for advanced non-small cell lung cancer with EGFR mutation positive patients.

Tagrisso 80mg tablet is also used for the treatment of patients affected with advanced EGFR T792M mutation positive NSCLC, disease has advanced on or after the tyrosine kinase inhibitor treatment.

MECHANISM OF ACTION

Tagrisso 80mg

PROPERTIES

Ingredients : Bevacizumab

Strength : 100mg/4ml

Package : 400mg of Bevacizumab containing vial

ADME PROPERTIES

Absorption :

High plasma concentration time of Osimeritinib reaches within 6 hours

Distribution :

Volume of distribution 918L
Human Plasma protein bound to Osimeritinib is 95%

Metabolism :

The metabolism of Osimeritinib is occurs via oxidation.
The Two pharmacologically active metabolite of Osimeritinib are AZ7550 & AZ5104

Excretion :

The mean terminal half-life period 48 hours
Clearance value 14.3L/hr
68% of metabolite is excreted in feces; 14% through urine
2% of unchanged form of drug is eliminated

DOSAGE MANAGEMENT

Tagrisso 80mg

The recommended dosage of Tagrisso 80mg tablets are, 80mg tablet should be taken as a single dose.
Tagrisso tablet should be administered with or without food.
If patient felt difficult to swallow the Tagrisso tablets as such, must disperse the tablet in 60ml of noncarbonated water and drink the solution immediately.
Tagrisso tablet do not break, crush or chew.

Interrupt the treatment during the conditions like;

Interstitial lung disease
QT prolongation
Symptomatic congestive heart failure
In pain management
Grade III or severe: discontinue the Tagrisso tablet for 3 weeks
Grade 0 to II: follow at 80mg or 40mg as a single dose
If no development in 3 weeks: Discontinue the therapy.
While co administration of Tagrisso with CYP3A4 inducers, the dosage of Tagrisso 80mg should be increased to 160mg as a single dose and followed by 80mg for 3 weeks after discontinuation of strong CYP3A4 inducers.

PRECAUTIONS

Interstitial lung disease:

Tagrisso 80mg

To avoid this problem, withheld or stop the Tagrisso 80mg tablets.

Keratitis:

Tagrisso 80mg

check the manifestation of keratitis regularly and provide supportive measures

Embryo fetal toxicity:

Tagrisso 80mg

Tagrisso 80mg tablet required in pregnancy period causes fetal damage.

QTc extension:

Do not concurrent use of Tagrisso 80mg with drug prolong the QTc

Cardiomyopathy:

Tagrisso 80mg

Periodic cardiac monitoring is assessed; in this condition stop the therapy.

SIDE EFFECTS

The most common adverse effects occurred during the therapy;
Cardiomyopathy, QT prolongation, Interstitial lung disease, Keratitis.

Other common side effect :

Diarrhea or constipation, Hyperglycemia, Hypomagnesemia, Hyponatremia, Elevation of AST & ALT, Stomatitis, Nausea, Vomiting, Rash, Nail toxicity, Pruritus, Dry skin, Headache, Cough, Dyspnea, Fatigue, Pyrexia, Loss of appetite, Respiratory tract infection, Lymphopenia, Thrombocytopenia, Anemia, Neutropenia.

PREGNANCY

Pregnancy category of Osimeritinib is not designate
While using Tagrisso 80mg tablet causes possible for fetal harm.

LACTATION

Milk feeding should not be taken during lactation period.

STORAGE

The Tagrisso 80mg tablet is, stored at 25°C.
Keep the tablet carton from moisture, heat and light.

MISSED DOSE

In case of missed dose, do not take the missed dose and follow the regular dosing schedule.

Health